Arrowhead Pharmaceuticals ($ARWR) Stock Hub 2026: Detailed SHASTA Phase 3 Data, Pancreatitis Reduction And The sHTG Filing Test

01Executive Summary

Arrowhead Pharmaceuticals ($ARWR) is a commercial-stage RNA interference company. The FDA approved its first wholly-owned medicine, REDEMPLO (plozasiran), on November 18, 2025 as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. The company is launching the quarterly subcutaneous therapy in the United States while using the same molecule to pursue a much larger severe-hypertriglyceridemia indication.

The most important new evidence is no longer a topline claim. At ESC 2026, Arrowhead presented detailed results from two global randomized, double-blind, placebo-controlled Phase 3 trials. Across 757 randomized patients, quarterly plozasiran 25 mg produced median triglyceride reductions of 79% and 81% at Month 12, met all prespecified secondary endpoints, and significantly reduced adjudicated acute-pancreatitis events in a prespecified pooled analysis. The broad-population event-rate result was RR 0.22 (95% CI 0.07-0.67; p=0.008), with 4.1% absolute risk reduction and a one-year NNT of 24. In the subgroup with triglycerides at least 500 mg/dL and prior pancreatitis, RR was 0.09 (95% CI 0.02-0.41; p=0.002), ARR 34% and NNT 3.

The safety table was broadly balanced overall but not featureless. Treatment-emergent adverse events occurred in 73% of both pooled groups; serious TEAEs were 8.3% with plozasiran and 10% with placebo; discontinuations were 1.4% and 0.8%. Worsening glycemic-control events and diarrhea were more frequent with plozasiran. Three deaths occurred in the plozasiran group and were attributed to pre-existing cardiovascular or hematologic disease and assessed by investigators as unrelated to treatment. That is the investigators’ causality assessment, not proof that regulators will treat the cases as irrelevant.

The wider company case also moved. A separate Chinese Phase 3 presentation reported that VSA003/zodasiran lowered LDL-C by 43.9 percentage points versus placebo at Month 6 in a 46-patient HoFH study. The global 70-patient YOSEMITE zodasiran trial remains a different program with completion guided to mid-2027. Financially, the June 30 Form 10-Q reported about $1.602 billion of gross cash, cash equivalents, restricted cash and available-for-sale securities, but Arrowhead also carries convertibles, a costly credit facility, future-royalty obligations, pre-funded warrants and an active ATM framework.

02Company Overview And The RNAi Platform

Arrowhead develops medicines that treat disease by silencing the specific genes that cause them, using the natural RNA interference mechanism. Its proprietary Targeted RNAi Molecule (TRiM) platform is engineered to deliver small-interfering RNA precisely into a wide range of tissues — not only the liver (where first-generation RNAi drugs were concentrated) but also lung, skeletal muscle, adipose tissue and the central nervous system. That breadth of delivery is the core of Arrowhead’s differentiation and the reason its pipeline spans cardiometabolic, pulmonary, neuromuscular and CNS diseases.

The company’s model has long been a hybrid: advance a set of wholly-owned assets toward the market while out-licensing others to large pharma partners in exchange for upfront cash, milestones and royalties. That strategy funded years of development and has now delivered its first approved product. Following the REDEMPLO approval, Arrowhead describes itself as a commercial-stage company, and its near-term narrative is about executing a launch and expanding a label rather than proving a platform that is now clinically and commercially validated.

Structurally, the important nuance for investors is that Arrowhead’s reported revenue is still overwhelmingly collaboration and licensing income — payments from partners recognized as programs hit milestones — rather than product sales. That makes the top line lumpy from quarter to quarter and means REDEMPLO’s commercial ramp, not the headline revenue number, is the metric to watch as the launch matures.

03REDEMPLO (plozasiran) — The First Approved Product

REDEMPLO (plozasiran) is an siRNA therapeutic designed to suppress the liver’s production of apoC-III, a protein that raises triglycerides by slowing their breakdown and clearance. By silencing apoC-III with a durable, quarterly subcutaneous injection, it produces large, sustained triglyceride reductions. It is the first and only siRNA approved for FCS studied in both genetically confirmed and clinically diagnosed patients.

The approved U.S. label is narrow but foundational: an adjunct to diet to reduce triglycerides in adults with FCS, dosed 25 mg subcutaneously once every three months, with no boxed warning and no contraindications. FCS is a severe rare disease — an estimated several thousand U.S. patients whose triglycerides can run ten to one hundred times normal, carrying a high risk of acute, recurrent and potentially fatal pancreatitis.

The launch so far

Arrowhead is commercializing REDEMPLO independently in the U.S. As of the May 7, 2026 update, the company reported:

• More than 400 prescriptions received and in process to date, described as greater than 40% growth over the prior four weeks.
• Approximately 180 patients had received at least one pre-filled-syringe shipment.
• About 30 new written prescriptions per week, and accelerating.
• Roughly 85% of prescriptions were for patients naive to the APOC3 class — a signal that physicians are finding and treating previously untreated FCS patients, rather than simply switching them from a rival drug.

Arrowhead set the U.S. wholesale acquisition cost at $45,000 per patient per year, a premium to the competing approved APOC3 inhibitor, under a “One-REDEMPLO” unified pricing model intended to hold the same price across FCS and severe hypertriglyceridemia if that broader indication is approved. Outside the U.S., REDEMPLO has received FCS approvals in Australia and China, a Health Canada Notice of Compliance, and an EU marketing authorization valid throughout the European Union issued on June 19, 2026 (announced June 22, 2026). Sanofi is responsible for commercialization in Greater China, while Arrowhead has stated that it intends to commercialize REDEMPLO directly in selected European markets.

04Plozasiran Label Expansion: What SHASTA Proved And What It Did Not

Design and population. SHASTA-3 and SHASTA-4 were global, randomized, double-blind, placebo-controlled Phase 3 studies in adults with severe hypertriglyceridemia on background therapy and diet. Participants were assigned 2:1 to plozasiran 25 mg or placebo once every three months for up to 12 months. The ESC deck shows 446 participants in SHASTA-3 (297 active, 149 placebo) and 311 in SHASTA-4 (207 active, 104 placebo), for 757 randomized. The pooled safety table contains 756 patients. The primary endpoint was percent change in fasting triglycerides from baseline at Month 12; all prespecified secondary endpoints were reported as met.

Triglycerides and thresholds. Median triglyceride changes at Month 12 were -79% in SHASTA-3 and -81% in SHASTA-4 (p<0.0001 in each comparison). Among patients starting at or above 880 mg/dL, the median reduction was 85% in both trials. At Month 12, 91% and 93% of evaluable treated patients reached less than 500 mg/dL, versus 51% and 50% with placebo; 52% and 55% reached less than 150 mg/dL, versus 7.9% and 2.0%. These responder analyses use visit-specific evaluable denominators, not every randomized patient.

Acute pancreatitis. In the prespecified pooled analysis, the rate of all positively adjudicated pancreatitis events was reduced by 78% versus placebo: RR 0.22, 95% CI 0.07-0.67, p=0.008. The deck defines positively adjudicated AP events as documented, probable or possible AP; the category should not be read as documented cases alone. The absolute event-rate reduction was 4.1%, corresponding to a one-year NNT of 24. Time to first adjudicated event also favored plozasiran: HR 0.26, 95% CI 0.09-0.78, p=0.016. Among 95 patients with triglycerides at least 500 mg/dL and a prior history of pancreatitis (60 active, 35 placebo), RR was 0.09, 95% CI 0.02-0.41, p=0.002; ARR was 34% and one-year NNT was 3. The presentation states a 100% event-rate reduction in the highest-risk subgroup with triglycerides at least 880 mg/dL and prior pancreatitis, but explicitly marks the underlying data as not shown. That headline therefore cannot be independently reconstructed from the deck.

Safety. In the pooled safety set, TEAEs occurred in 73% of both groups; serious TEAEs in 8.3% of active and 10% of placebo patients; severe TEAEs in 8.3% and 10%; and treatment discontinuations in 1.4% and 0.8%. Worsening glycemic-control events were 14.3% versus 8.7%, diarrhea 5.6% versus 3.2%, and injection-site reactions 3.2% versus 2.0%. Three fatal serious events occurred in the active group: cardiogenic shock after acute myocardial infarction, sudden cardiac death in extensive cardiovascular disease, and chronic myelomonocytic leukemia. The presentation says all were attributable to pre-existing disease and assessed as unrelated to treatment. There were no anaphylaxis or systemic hypersensitivity cases, no clinically meaningful platelet change, no meaningful liver-enzyme imbalance, no Hy’s law cases, and no statistically significant treatment-emergent increase in liver fat in the small MRI-PDFF substudy (p=0.70).

Publication and regulatory status. As of the fixed cutoff, ClinicalTrials.gov listed SHASTA-3 and SHASTA-4 without posted results, and the detailed dataset was available as a company-sponsored conference presentation rather than a peer-reviewed full publication. Arrowhead intends to combine SHASTA-3, SHASTA-4 and the larger MUIR-3 safety study for filings in multiple geographies, beginning with a U.S. supplemental NDA before the end of 2026. The company plans to use a purchased Priority Review Voucher. No sHTG PDUFA date exists because the supplement has not been filed and accepted.

05The Wholly-Owned Cardiometabolic & Obesity Pipeline

Beyond plozasiran, Arrowhead is building a multi-asset cardiometabolic and obesity franchise — the area where it keeps the most economics.

Zodasiran (ARO-ANG3)

Zodasiran silences ANGPTL3, a validated lipid target, and is being advanced in Phase 3 with a focus on homozygous familial hypercholesterolemia (HoFH) in the YOSEMITE study. ANGPTL3 knockdown lowers multiple atherogenic lipids, positioning zodasiran as a second wholly-owned cardiometabolic pillar behind plozasiran.

On July 27, 2026 Arrowhead announced that enrollment in YOSEMITE (NCT07037771) is complete. The global, multicentre, randomised, double-blind, placebo-controlled study enrolled 70 patients against an original design of 60, randomised 2:1 to four quarterly doses of 200 mg zodasiran or placebo. Participants are over the age of 12 and already on maximally tolerated lipid-lowering therapy; the primary endpoint is the percent change in fasting LDL-C from baseline to month 12, with an optional open-label extension afterwards. Study completion is guided to mid-2027, with regulatory submissions in multiple geographies to follow if the data support them.

China Phase 3 VSA003 readout: the ESC presentation on August 31 reported 46 Chinese adolescents and adults with HoFH, 30 on VSA003 and 16 on placebo. At Month 6, the active arm changed -44.8% in LDL-C versus -0.9% with placebo, an LS mean difference of -43.9 percentage points (p<0.0001). ANGPTL3 fell by an LS mean difference of 86.2% versus placebo; ApoB, non-HDL-C, triglycerides and Lp(a) also improved. TEAEs occurred in 76.7% versus 75.0%; serious adverse events in 10.0% versus 6.3%; no serious event was judged treatment-related. One active-arm sudden cardiac death in a patient with multiple risk factors was assessed by the investigator as unrelated. Three liver-finding events occurred on active therapy and the deck describes two additional moderate treatment-related enzyme events in participants with abnormal baseline enzymes. The study is small, China-specific and did not test cardiovascular outcomes; it should not be conflated with global YOSEMITE.

The mechanistic argument is specific to this population. HoFH is usually caused by mutations in the LDL receptor gene, so therapies that depend on a functioning receptor lose potency exactly where the disease is most severe; reducing ANGPTL3 lowers atherogenic lipoproteins through a different route. Zodasiran carries FDA Orphan Drug Designation for HoFH, and in the Phase 2 GATEWAY study in HoFH patients there were no drug discontinuations, no drug-related serious adverse events and no deaths, with the most frequent adverse events being COVID-19, nasopharyngitis, upper respiratory tract infection and dizziness. Untreated, median LDL-C in HoFH can exceed 400 mg/dL, and estimated global prevalence is between 1 in 360,000 and 1 in 250,000 — a small population, which is what makes the enrollment overshoot notable and also what caps the commercial size of this indication on its own.

Obesity — ARO-INHBE and ARO-ALK7

Arrowhead’s RNAi approach to obesity is one of its most-watched early stories. In interim Phase 1/2a data reported through May 2026:

• ARO-INHBE combined with tirzepatide drove -9.4% weight loss at week 16 in obese patients with type 2 diabetes — roughly double the -4.8% on tirzepatide alone — plus large reductions in visceral, total and liver fat.
• ARO-ALK7 became the first RNAi therapeutic to show knockdown of an adipocyte-expressed gene in humans, achieving a mean -88% reduction in ALK7 mRNA and a -14.1% placebo-adjusted visceral-fat reduction from a single dose.

At EASL 2026, Arrowhead also reported that a single 400 mg dose of ARO-INHBE produced a mean maximum 85.3% reduction in Activin E with an effect persisting beyond three months. In a small subgroup with elevated baseline liver fat, doses of 200 mg or more produced a 44% placebo-adjusted reduction in liver fat; continued improvements in visceral and liver fat were observed from week 12 to week 24. These remain interim, early-stage data from small cohorts.

The thesis is that RNAi could complement or extend incretin (GLP-1/GIP) therapies by improving body composition — preserving the quality of weight loss — with an infrequent dosing schedule.

ARO-DIMER-PA

Arrowhead reported Phase 1/2a interim topline results on September 15. Mean maximal single-dose reductions were 72% for PCSK9 and 88% for APOC3, with LDL-C down 54%, triglycerides 73%, non-HDL cholesterol 61% and ApoB 50%. These are company-reported biomarker changes, not demonstrated reductions in cardiovascular events or placebo-adjusted outcome benefits. Safety and evidence limits above.

06The Partnership Engine

Much of Arrowhead’s value — and most of its current revenue — sits in a network of large-pharma collaborations. These deals fund the platform and de-risk assets, but they also mean the biggest late-stage readouts are partner-controlled and, in several cases, years away.

The Sarepta question

Because Sarepta had a difficult 2025 in unrelated programs, investors reasonably ask whether the 2024 Arrowhead license — worth $500 million upfront, $325 million in equity, $250 million in annual installments and up to roughly $10 billion in potential milestones — is still solid. Arrowhead addressed this directly in a July 23, 2025 statement confirming the agreement was intact and that it expected Sarepta to meet its obligations. The subsequent filings support that: the near-term ARO-DM1 milestone package was paid, the first $50 million annual installment was received on schedule in February 2026, and a December 2025 clinical-supply agreement is already generating revenue. Contract protections also let Arrowhead terminate the deal if any installment is missed.

07Financials And Runway

At June 30, 2026, Arrowhead reported $54.8 million of cash, cash equivalents and restricted cash, including $4.1 million of restricted cash, plus $1,547.2 million of available-for-sale securities. The combined gross resource figure was about $1.602 billion. The cash total includes $35.1 million held at the consolidated Visirna variable-interest entity, so it should not be treated as a simple parent-only cash balance. Nor is the gross figure net cash: convertibles, the Sixth Street facility, leases and the future-royalty liability remain.

Revenue increased to $75.3 million, driven primarily by collaboration and licence accounting and partially by commercial revenue from REDEMPLO. Arrowhead did not separately disclose a complete product-sales line in the filing. R&D rose to $198.2 million and SG&A to $47.1 million as the company funded multiple trials, manufacturing preparation and a commercial launch. Nine-month operating cash use was $79.5 million, but that figure benefited from large collaboration, milestone and annual-fee receipts and therefore is not a clean recurring burn-rate estimate.

Management stated only that current cash and investment resources were expected to fund operations for at least twelve months from issuance of the June-quarter statements. The filing did not provide a precise multi-year runway date. The balance sheet reduces near-term financing pressure, but it does not remove allocation, dilution or execution risk.

08Capital Structure And Dilution

The July 30, 2026 Form 10-Q cover reported 141,254,467 common shares outstanding. The June 30 balance-sheet table showed 141.135 million common shares and explicitly excluded shares issuable through the 2024 and 2026 Avoro pre-funded warrants. Those warrants covered 917,441 and 1,550,387 shares, respectively; the filing said none had been exercised at June 30. They are economically close to common shares despite not appearing in the basic count.

The January 2026 financing combined $700 million of 0.00% convertible senior notes due 2032, 2,015,505 common shares at $64.50 and pre-funded warrants for 1,550,387 shares at $64.499, for $930 million of gross proceeds across the note and equity components. The initial conversion price was approximately $87.08 and Arrowhead bought capped calls with an initial cap near $119.33. Capped calls may reduce dilution in specified ranges; they do not eliminate it.

Arrowhead also retains an ATM program of up to $500 million. During the June quarter it sold approximately 367,000 shares for $28.0 million gross and $27.2 million net; across the first nine fiscal months it sold approximately 1.056 million shares for $76.1 million gross and $74.1 million net. The correct current read is therefore an actively used financing tool, not an unused standby facility.

On the liability side, the June balance sheet included $682.7 million of convertible notes, net, $181.4 million drawn on the high-cost Sixth Street credit facility and $392.5 million of liability related to the sale of future royalties. These instruments differ economically and should not be added as if they were identical ordinary debt, but all matter when translating gross liquidity into value attributable to common equity.

09Merlintrader Health Score

Editorial 1–5 score on 12–18 month robustness/fragility across five pillars. It is not a buy/sell signal.

Reading: a first approved product, successful pivotal SHTG data, a deep partnered platform, a funded balance sheet and an unusually dense catalyst calendar anchor the score. Offsets are a complex capital structure (convertible notes, a high-cost credit facility, a royalty monetization), a still-immaterial product ramp, regulatory and commercial work still required for SHTG, and normal clinical risk in the earlier obesity/CNS programs. The 4/5 reflects robustness and optionality, not a buy/sell view. Merlintrader editorial assessment, not advice.

10Competitive Landscape

Arrowhead competes on two fronts: as an RNAi platform and, more concretely, in the triglyceride/apoC-III market it just entered.

In FCS and hypertriglyceridemia, the most direct rival is Ionis Pharmaceuticals‘ olezarsen (Tryngolza), an antisense apoC-III drug approved in the U.S. for FCS ahead of REDEMPLO. Arrowhead’s pitch is a differentiated profile and its quarterly dosing versus more frequent injection, with the premium $45,000 price framed as supported by clinical evidence. Arrowhead has now reported successful Phase 3 SHTG results, including deep triglyceride reductions and a statistically significant pancreatitis signal. The competitive comparison will depend on the detailed SHASTA dataset, including absolute effects and safety, label breadth, safety, dosing convenience, pricing, reimbursement, physician adoption and the timing and strength of Ionis’s own SHTG expansion package.

Patent litigation is an additional risk. Arrowhead filed a declaratory-judgment action in September 2025 seeking a ruling that an Ionis patent was invalid and not infringed; that action was dismissed on December 23, 2025. Ionis separately filed a patent-infringement complaint alleging that commercialization of plozasiran infringes the same patent and seeking damages. Arrowhead disputes the allegations and has stated that it intends to defend itself vigorously. The June 30, 2026 Form 10-Q did not record a material contingent liability for the matter, but the case remains a legal overhang tied directly to the lead commercial asset.

In RNAi broadly, Alnylam Pharmaceuticals is the category leader with multiple approved liver-targeted medicines and a large commercial base, while Ionis (antisense) and others compete for the same lipid and rare-disease targets. Arrowhead’s differentiation is the TRiM platform’s reach beyond the liver — into lung, muscle, adipose and CNS — which underpins programs (obesity, neuromuscular, pulmonary) that pure liver-RNAi peers cannot easily match.

In obesity, Arrowhead is a newcomer against the incretin giants (Novo Nordisk, Eli Lilly) and a crowded field of next-generation entrants. Its angle is not to beat GLP-1s head-on but to complement them on body composition with infrequent RNAi dosing — a thesis that still has to prove itself in larger trials.

11Management

Christopher Anzalone, Ph.D., co-founder, is President, Chief Executive Officer and Board Chair, and has led Arrowhead through its long build from platform company to commercial launch. Daniel Apel serves as Chief Financial Officer, James Hamilton, M.D. as Chief Medical Officer and Head of R&D, and Patrick C. O’Brien as Chief Operating Officer.

For a company pivoting to commercial execution while running Phase 3 trials and a heavy business-development cadence, the leadership continuity at the top — and the addition of experienced financial and clinical operators — is a stabilizing factor. (Investor-relations contact is handled by Vince Anzalone, CFA, VP of Investor Relations, who is not the CFO — a common point of confusion.)

12What Bulls See

The constructive case is that Arrowhead has crossed two high-risk thresholds: it has an approved, launching product, and the same asset has now succeeded in two large registrational SHTG studies. Plozasiran’s planned label expansion targets a population many multiples the size of FCS, while the pancreatitis result gives the story a clinically meaningful dimension beyond laboratory triglyceride lowering. The quarterly dosing profile, clean topline safety language and Breakthrough Therapy designation may support a differentiated regulatory and commercial proposition. The wholly-owned obesity programs (ARO-INHBE, ARO-ALK7) add longer-duration upside, while the partnership roster — Amgen, Takeda, Sarepta, Novartis, Madrigal and GSK — validates the platform and can provide milestone and royalty income. With approximately $1.602 billion of gross liquidity at June 30, bulls argue Arrowhead is entering a multi-year transition from an RNAi platform with a rare-disease launch into a broader cardiometabolic commercial company.

13What Bears See

The skeptical view starts with the gap between a successful clinical package and durable cash flows. REDEMPLO is early and small in FCS: product revenue is not yet separately disclosed, and the launch has to prove it can scale before it materially changes the P&L. The detailed SHTG dataset is clinically strong, but Arrowhead must still file an acceptable sNDA, file an acceptable sNDA, obtain the desired label, win payer access and compete effectively against olezarsen. Meanwhile the company is burning heavily — R&D of $173 million in a single quarter — and reported revenue is dominated by lumpy collaboration income. The capital structure remains more complex than the gross cash suggests: a $700 million convertible, a high-cost Sixth Street facility, pre-funded warrants, an ATM program and a Royalty Pharma monetization all matter. Several other major value drivers remain partner-controlled or early-stage.

Key Red Flags To Monitor

• Launch scale: REDEMPLO revenue is still immaterial and must demonstrate a durable ramp; FCS alone is a small market.
• Full SHASTA dataset: topline results are strong, but detailed event counts, confidence intervals, subgroup sizes, discontinuations and the complete safety dataset remain to be presented and published.
• Regulatory and access risk: the sNDA has not yet been filed or accepted, no SHTG PDUFA date exists, the final label is unknown and payer adoption in a broad chronic population may be demanding.
• Cash burn vs. revenue quality: large R&D spend against lumpy, partnership-driven revenue rather than mature product sales.
• Capital-structure complexity: convertible notes, pre-funded warrants, the still-available ATM, the Sixth Street facility and the Royalty Pharma liability mean fully diluted equity and net financial resources differ materially from the simple basic-share and gross-cash figures.
• Patent litigation: Ionis alleges that commercialization of plozasiran infringes a U.S. patent; Arrowhead disputes the claim, but the case creates legal and potential economic uncertainty around the lead product.
• Partner dependence: marquee late-stage catalysts such as olpasiran and fazirsiran are partner-controlled and years out.
• Competition: Ionis in apoC-III, Alnylam in RNAi and incretin leaders in obesity.

14Scenario Framework

The following scenarios are descriptive ways to think about how the story could evolve. They are not price targets, forecasts or recommendations.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

15Bottom Line

Arrowhead Pharmaceuticals has done two difficult things: it turned its RNAi platform into an approved, launching product, and it has now extended that product’s clinical validation into a much larger severe-hypertriglyceridemia population. SHASTA-3 and SHASTA-4 met the primary endpoint and all prespecified secondary endpoints, with 79% and 81% median triglyceride reductions and a statistically significant pooled reduction in acute-pancreatitis events. The reported 78% event reduction in the broad SHTG population and 100% reduction in the predefined highest-risk subgroup make this more than a laboratory-biomarker readout.

The result materially improves the SHTG expansion thesis, but the next phase is execution rather than celebration. Investors still need regulators to interpret the detailed ESC dataset, the MUIR-3 safety contribution, the sNDA filing and acceptance, the eventual FDA label, payer access and real-world market uptake. Those tasks sit alongside the existing FCS launch, the Ionis patent dispute, substantial R&D spending, a complex capital structure and a broad pipeline that requires disciplined capital allocation.

For a stock hub, the honest framing remains a scorecard, not a verdict. The three central tracking points are now the REDEMPLO commercial ramp, the SHASTA regulatory path and planned sNDA, and the early obesity/cardiometabolic readouts that determine how far beyond plozasiran the platform can reach. The cash, partnerships and TRiM breadth provide resilience and optionality, but they do not remove execution risk.